myAACR
Donate Today
myAACR
Donate Today

Progress Against Cancer

Home Patients, Caregivers, and Advocates Progress Against Cancer Research Page 125

Recent Progress

Marching Forward on Multiple Fronts: March is Multiple Myeloma Awareness Month

Marching Forward on Multiple Fronts: March is Multiple Myeloma Awareness Month

Multiple myeloma is a cancer of antibody-producing cells – called plasma cells – that accounts for approximately 1.8 percent of new cancer cases in the United States. Although it is a relatively uncommon cancer, those who are diagnosed face a five-year survival rate of only 52 percent. Patients who are diagnosed at an early stage generally have a better prognosis; however, almost all patients are diagnosed after the cancer has progressed to a more advanced stage.

CANCER RESEARCH CATALYST
Learn More
Kidney Cancer: Examining Risk Factors and Recently Approved Treatments

Kidney Cancer: Examining Risk Factors and Recently Approved Treatments

A highly complex filtering system, the kidneys process roughly half a cup of blood every minute, isolating waste and returning minerals and nutrients to the bloodstream. Renal cell carcinoma, a cancer that develops in the lining of the renal tubules, is the most common type of kidney cancer in adults, representing 85 percent of kidney and ureter cancers. Other types of kidney and ureter cancer can develop in the renal pelvis, the funnel where urine flows from the kidney to the bladder.

CANCER RESEARCH CATALYST
Learn More
AACR Conference on the Microbiome, Viruses, and Cancer: Regulating Microbes to Reduce Chemotherapy Toxicity

AACR Conference on the Microbiome, Viruses, and Cancer: Regulating Microbes to Reduce Chemotherapy Toxicity

“There’s a clear connection between cancer and the gut microbiome,” began Matthew Redinbo, PhD, of the University of North Carolina at Chapel Hill, at the opening keynote address during the recent AACR special conference The Microbiome, Viruses, and Cancer, held in Orlando. Redinbo, a professor of chemistry, biochemistry, and microbiology, noted that there is an “intimate chemical relationship” linking specific microbiota with cancer progression, and that certain bacteria can also modulate patient’s responses to cancer treatment, representing an untapped area of drug discovery.

CANCER RESEARCH CATALYST
Learn More
Examining Diverse Uses for Liquid Biopsies

Examining Diverse Uses for Liquid Biopsies

Circulating tumor DNA (ctDNA) was first detected over 30 years ago, but its potential uses for cancer diagnosis and treatment are only recently being extensively explored. An emerging method known as liquid biopsy examines ctDNA, cell-free DNA (cfDNA), or circulating tumor cells in blood plasma samples to learn about the patient’s cancer without needing to resect tissue from the tumor itself, as is typically required in traditional diagnostic and staging methods. Liquid biopsy could, therefore, provide a minimally invasive technique to detect and characterize cancer and to monitor its response to treatment.

CANCER RESEARCH CATALYST
Learn More
Search / Filter
Innovators in Discovery

AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.

Learn More
Also of Interest: